Ascendis Pharma A/S (ASND)
Develops long-acting hormone therapies for growth disorders and rare endocrine diseases.
$254.44+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+45.8%
The outlook
ASND is trading near the top of its 52-week range, well above its moving averages, with analyst consensus strongly bullish. The average analyst target sits roughly 20% above the current price of $254.44. The stock carries a trailing P/E of 29.6, reflecting a premium valuation in the current market environment.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 18 analysts
Price trendAbove its 50- & 200-day averages
52-week range77% of the way from its 52-week low to high
Price targetAvg target +20% vs current price
Analyst price target
~12-month · 18 analysts$305.01average target+19.9% vs now
Now $254.44
Low $257.23High $353.46
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$16.69B
52-wk high
$282.15
52-wk low
$160.86
50-day avg
$243.82
200-day avg
$225.42
Trailing P/E
29.6